<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="ea1" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">ea1</book-part-id>
      <title-group>
        <title>Episodic Ataxia Type 1</title>
        <alt-title alt-title-type="alt-title">Synonyms: EA1, Episodic Ataxia with Myokymia</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>D&#x02019;Adamo</surname>
            <given-names>Maria Cristina</given-names>
          </name>
          <degrees>PhD</degrees>
          <email>maria.dadamo@unipg.it</email>
          <aff>Section of Physiology and Biochemistry<break/>University of Perugia School of Medicine<break/>Perugia, Italy</aff>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2010-02-09" date-type="created">
          <day>9</day>
          <month>2</month>
          <year>2010</year>
        </date>
        <date iso-8601-date="2015-06-25" date-type="updated">
          <day>25</day>
          <month>6</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="gale-def" document-type="chapter">Epimerase Deficiency Galactosemia</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="ea2" document-type="chapter">Episodic Ataxia Type 2</related-object>
      <abstract id="ea1.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Episodic ataxia type 1 (EA1) is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks individuals may experience a number of variable symptoms including vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing, among others. EA1 may be associated with epilepsy. Other findings can include delayed motor development, cognitive disability, choreoathetosis, and carpal spasm. Usually, onset is in childhood or early adolescence.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis is based on clinical findings, an electrophysiologic test of axonal superexcitability and threshold electrotonus, and/or molecular genetic testing of <italic toggle="yes">KCNA1,</italic> the only gene in which pathogenic variants are known to cause EA1.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Acetazolamide (ACTZ), a carbonic-anhydrase (CA) inhibitor, may reduce the frequency and severity of the attacks in some but not all affected individuals. Antiepileptic drugs (AEDs) may significantly reduce the frequency of the attacks in some individuals.</p>
          <p><italic toggle="yes">Prevention of primary manifestations</italic>: In addition to pharmacologic treatments, behavioral measures including avoidance of stress, abrupt movements, loud noises, and caffeine intake may be used to reduce disease manifestations in both symptomatic and asymptomatic individuals.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Joint contractures can be prevented by appropriate physiotherapy.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual neurologic examination.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Triggers of attacks, including physical exertion, emotional stress, and changes in environmental temperature; marked generalized myokymia has been reported during induction of anesthesia.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Affected women should be made aware that pregnancy may trigger attacks; possible loss of balance and falls could endanger the fetus. Several stressors that trigger attacks may cause breathing difficulties, thus, delivery by C-section should be considered.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>EA1 is inherited in an autosomal dominant manner. Most individuals diagnosed with EA1 have an affected parent; however, <italic toggle="yes">de novo</italic> pathogenic variants have been reported. Each child of an individual with EA1 has a 50% chance of inheriting the <italic toggle="yes">KCNA1</italic> pathogenic variant. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant has been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="ea1.Diagnosis">
        <title>Diagnosis</title>
        <sec id="ea1.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Episodic ataxia type 1 (EA1) <bold>should be suspected</bold> in individuals with the following clinical, imaging, and laboratory findings:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Clinical manifestations</bold> including:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Episodic attacks of:</p>
                  <list list-type="bullet">
                    <list-item>
                      <p>Generalized ataxia, loss of balance, and jerking movements of the head, arms, and legs</p>
                    </list-item>
                    <list-item>
                      <p>Dysarthria</p>
                    </list-item>
                    <list-item>
                      <p>Incoordination of hands</p>
                    </list-item>
                    <list-item>
                      <p>Weakness</p>
                    </list-item>
                    <list-item>
                      <p>Tremors</p>
                    </list-item>
                    <list-item>
                      <p>Muscle twitching/stiffening</p>
                    </list-item>
                    <list-item>
                      <p>Dizziness</p>
                    </list-item>
                    <list-item>
                      <p>Stiffening of the body</p>
                    </list-item>
                    <list-item>
                      <p>Blurred vision, diplopia</p>
                    </list-item>
                    <list-item>
                      <p>Nausea, headache, and vomiting</p>
                    </list-item>
                  </list>
                </list-item>
                <list-item>
                  <p>Neuromyotonia (muscle cramps and stiffness)</p>
                </list-item>
                <list-item>
                  <p>Myokymia (muscle twitching with a rippling appearance) occurring in the limbs or especially in the muscles of the face or hands</p>
                </list-item>
                <list-item>
                  <p>Childhood or early-adolescent disease onset (average age of onset: ~8 years)</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Normal brain MRI and routine laboratory blood tests</bold> including serum concentration of creatine kinase and electrolytes</p>
            </list-item>
            <list-item>
              <p><bold>EMG</bold> that displays a pattern of either rhythmically or arrhythmically occurring singlets, duplets, or multiplets Note: In some individuals myokymic activity on the EMG becomes apparent after the application of regional ischemia.</p>
              <list list-type="bullet">
                <list-item>
                  <p>To evaluate for interictal motor activity (neuromyotonia/myokymia): surface or needle EMG recordings are performed before, during, and after the application of regional ischemia (e.g., using an inflated sphygmomanometer cuff applied around the upper or lower arm for up to 15 minutes).</p>
                </list-item>
                <list-item>
                  <p>In specialized centers, electrophysiologic assessments of axonal super-excitability and threshold electrotonus performed according to the TRONDHM protocol (using Qtrac&#x000a9; software; UCL Institute of Neurology [<xref ref-type="bibr" rid="ea1.REF.kiernan.2000.399">Kiernan et al 2000</xref>]) allows differentiation of individuals with EA1 from normal controls with high sensitivity and specificity [<xref ref-type="bibr" rid="ea1.REF.tomlinson.2010.3530">Tomlinson et al 2010</xref>].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>Family history</bold> consistent with autosomal dominant inheritance</p>
            </list-item>
          </list>
          <p>Note: Muscle biopsy is usually not helpful in establishing the diagnosis, although bilateral calf hypertrophy, enlargement of type 1 and type 2 gastrocnemius muscle fibers, and variable glycogen depletion have been observed [<xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al 1975</xref>, <xref ref-type="bibr" rid="ea1.REF.kinali.2004.689">Kinali et al 2004</xref>, <xref ref-type="bibr" rid="ea1.REF.demos.2009.778">Demos et al 2009</xref>]. Nevertheless, these changes have not been consistently reported among individuals with EA1.</p>
        </sec>
        <sec id="ea1.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of EA1 <bold>can be established</bold> in a proband by means of electrophysiology assessments and/or by the finding of a heterozygous pathogenic variant in <italic toggle="yes">KCNA1</italic>.</p>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel.</bold></p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">KCNA1</italic> is recommended first. Although no deletions of <italic toggle="yes">KCNA1</italic> have been reported to cause EA1, it is theoretically possible that such deletions have occurred. Therefore, deletion/duplication analysis may be useful in individuals displaying EA1 symptoms if sequence analysis does not identify a <italic toggle="yes">KCNA1</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">KCNA1</italic> and other genes of interest (see <xref ref-type="sec" rid="ea1.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and the sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="ea1.T.molecular_genetic_testing_used_in" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Episodic Ataxia Type 1</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by this Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">KCNA1</italic>
                  </td>
                  <td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_ea1.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup>; none reported</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="ea1.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="ea1" object-id="ea1.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="ea1.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="ea1.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="ea1.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="ea1.TF.1.4">
                <label>4. </label>
                <p>All affected individuals described thus far are heterozygous for <italic toggle="yes">KCNA1</italic> pathogenic variants at amino acid residues highly conserved among the voltage-dependent K<sup>+</sup> channel superfamily.</p>
              </fn>
              <fn id="ea1.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="ea1.TF.1.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Interpretation of test results.</bold> For <italic toggle="yes">KCNA1</italic> sequence variants, publications on in vitro assessment of channel function may be useful [<xref ref-type="bibr" rid="ea1.REF.d_adamo.1998.1200">D&#x02019;Adamo et al 1998</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2008.577">Imbrici et al 2008</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>]. Channel function assays are not offered on a clinical testing basis.</p>
        </sec>
      </sec>
      <sec id="ea1.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="ea1.Clinical_Description">
          <title>Clinical Description</title>
          <p>Episodic ataxia type 1 (EA1), first described in 1975 by VanDyke et al, is a potassium channelopathy characterized by constant myokymia and dramatic episodes of spastic contractions of the skeletal muscles of the head, arms, and legs with loss of both motor coordination and balance. During attacks some individuals may experience vertigo, blurred vision, diplopia, nausea, headache, diaphoresis, clumsiness, stiffening of the body, dysarthric speech, and difficulty in breathing [<xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al 1975</xref>].</p>
          <p>The duration of the attacks is brief, lasting seconds to minutes, although prolonged attacks lasting hours have been described [<xref ref-type="bibr" rid="ea1.REF.lee.2004a.536">Lee et al 2004a</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>]. Episode occurrence is variable, with some individuals experiencing severe ataxia more than 15 times per day and others experiencing attacks less often than once a month [<xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al 1975</xref>].</p>
          <p>The first symptoms typically manifest during childhood (1st or 2nd decade of life). A specific traumatic physical or emotional event may determine the onset and worsening of the disease [<xref ref-type="bibr" rid="ea1.REF.imbrici.2008.577">Imbrici et al 2008</xref>]. Attacks may be brought on by stimuli including stress, emotional upset, anxiety, fatigue, menstruation, pregnancy, environmental temperature, fever, startle response, abrupt movements, sudden postural changes (kinesigenic stimulation), vestibular stimulation (head turning from side to side while standing still; sitting still on a rotating chair; instillation of cold water (i.e., &#x02264;30&#x000b0; C) into either external auditory canal), repeat knee bends, exercise, ingestion of caffeine or alcohol, and riding a merry-go-round. Attacks may occur, for example, when the individual has had to suddenly alter course to avoid falling or potential collision. High temperatures that occur after a hot bath or during use of a hairdryer may also precipitate attacks [<xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>]. Whether interictal ataxia develops in individuals with EA1 has not been clearly reported to date.</p>
          <p>Myokymia manifests clinically during and between attacks as fine twitching of groups of muscles and intermittent cramps and stiffness. Usually, it is evident as a fine rippling in perioral or periorbital muscles and by lateral finger movements when the hands are held in a relaxed, prone position.</p>
          <p>Rarely, episodes of intense myokymic activity during attacks without either ataxia or other neurologic deficits are observed. Myokymic activity is continuous and present in almost all affected patients [<xref ref-type="bibr" rid="ea1.REF.lee.2004b.3161">Lee et al 2004b</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>].</p>
          <p>The exposure of the forearm to warm or cold temperatures may increase or decrease, respectively, the spontaneous activity recorded from a hand muscle.</p>
          <p>The severity of some symptoms may either improve or worsen with age [<xref ref-type="bibr" rid="ea1.REF.imbrici.2008.577">Imbrici et al 2008</xref>].</p>
          <p>Since the first description of EA1 by <xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al [1975]</xref> and the identification and characterization of pathogenic variants in <italic toggle="yes">KCNA1</italic>, the phenotypic spectrum of EA1 has widened considerably [<xref ref-type="bibr" rid="ea1.REF.graves.2014.1009">Graves et al 2014</xref>], indicating that it is not a purely cerebellar syndrome. Affected individuals may display delayed motor development, choreoathetosis, carpal spasm, clenching of the fists, and isolated neuromyotonia.</p>
          <p>Cognitive dysfunction described in EA1 includes severe receptive and expressive language delay; inability to learn to ride a bicycle; and the need for life-skill programs or schools for children with mild to moderate learning difficulties [<xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.demos.2009.778">Demos et al 2009</xref>].</p>
          <p>Moderate muscle hypertrophy with generalized increase in muscle tone and bilateral calf hypertrophy are observed. Neuromuscular findings secondary to the increased tone include unusual hypercontracted posture; abdominal wall muscle contraction; elbow, hip, and knee contractures; and shortened Achilles tendons that may result in tiptoe walking.</p>
          <p>Some individuals display attacks of difficulty in breathing, which can occur during ataxic episodes or as isolated episodes of an inability to inhale without wheezing [<xref ref-type="bibr" rid="ea1.REF.shook.2008.399">Shook et al 2008</xref>].</p>
          <p>Skeletal deformities including scoliosis, kyphoscoliosis, high-arched palate, and minor craniofacial dysmorphism have been described [<xref ref-type="bibr" rid="ea1.REF.kinali.2004.689">Kinali et al 2004</xref>, <xref ref-type="bibr" rid="ea1.REF.klein.2004.147">Klein et al 2004</xref>]. It is now apparent that phenotypic differences exist not only across families, but also among affected individuals within a family.</p>
          <p>Tonic-clonic and partial seizures, an isolated episode consisting of photo-sensitive epilepsy [<xref ref-type="bibr" rid="ea1.REF.imbrici.2008.577">Imbrici et al 2008</xref>], as well as head-turning and eyes deviating to the same side, flickering eyelids, lip-smacking, apnea, and cyanosis have been reported [<xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al 1999</xref>].</p>
          <p>Abnormal electroencephalograms (EEG) have been observed in persons with EA1 [<xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al 1975</xref>, <xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.lee.2004a.536">Lee et al 2004a</xref>]. EEG may be characterized by intermittent and generalized slow activity, frequently intermingled with spikes. <xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al [1999]</xref> described a boy age three years who presented with an ictal EEG with rhythmic slow-wave activity over the right hemisphere, becoming spike-and-wave complexes that subsequently spread to the left hemisphere.</p>
          <p>Neuromimaging with MRI is usually normal; however, <xref ref-type="bibr" rid="ea1.REF.demos.2009.778">Demos et al [2009]</xref> reported a family with cerebellar atrophy.</p>
        </sec>
        <sec id="ea1.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Due to significant interfamilial and intrafamilial phenotypic variability, reliable genotype-phenotype correlations have been extremely difficult to establish. Indeed, differences in severity and frequency of EA1 attacks have been reported even in monozygotic twins [<xref ref-type="bibr" rid="ea1.REF.graves.2010.367">Graves et al 2010</xref>].</p>
        </sec>
        <sec id="ea1.Penetrance">
          <title>Penetrance</title>
          <p>Most individuals harboring a <italic toggle="yes">KCNA1</italic> pathogenic variant exhibit features of EA1; however, penetrance is incomplete.</p>
        </sec>
        <sec id="ea1.Nomenclature">
          <title>Nomenclature</title>
          <p>EA1 has also been known as:</p>
          <list list-type="bullet">
            <list-item>
              <p>Familial paroxysmal kinesigenic ataxia and continuous myokymia</p>
            </list-item>
            <list-item>
              <p>Acetazolamide-responsive periodic ataxia</p>
            </list-item>
            <list-item>
              <p>Continuous muscle fiber activity</p>
            </list-item>
            <list-item>
              <p>Isaacs-Mertens syndrome</p>
            </list-item>
          </list>
        </sec>
        <sec id="ea1.Prevalence">
          <title>Prevalence</title>
          <p>EA1 is a rare disease and the prevalence can be estimated only roughly. Several families from Australia, Brazil, Canada, Germany, Italy, Russia, Spain, the Netherlands, United Kingdom, and the United States have been described. Based on limited data, a disease prevalence of 1:500,000 has been proposed. Actual prevalence may well be considerably higher, as the disorder may remain either unrecognized in many families or be incorrectly diagnosed.</p>
          <p>The populations that are more or less at risk are also unknown.</p>
        </sec>
      </sec>
      <sec id="ea1.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al [2015]</xref> reported a unique phenotype characterized by episodes of long-lasting attacks with hyperthermia, short sleep duration, and severe migraine. <xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al [2000]</xref> reported on isolated neuromyotonia without episodes of ataxia. It is unclear whether these truly represent unique phenotypes associated with a pathogenic variant in <italic toggle="yes">KCNA1</italic> or fall within the phenotypic spectrum of episodic ataxia type 1.</p>
        <p>Hypomagnesemia with accompanying recurrent muscle cramps, tetanic episodes, tremor, and limb muscle weakness has been described in a large Brazilian family harboring a <italic toggle="yes">KCNA1</italic> pathogenic variant [<xref ref-type="bibr" rid="ea1.REF.glaudemans.2009.936">Glaudemans et al 2009</xref>].</p>
      </sec>
      <sec id="ea1.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Episodic ataxia can occur sporadically or in a number of hereditary disorders.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="ea2" document-type="chapter"><bold>Episodic ataxia type 2</bold></related-object>
<bold>(EA2)</bold> is characterized by paroxysmal attacks of ataxia, vertigo, and nausea lasting minutes to days. Attacks can be associated with dysarthria, diplopia, tinnitus, dystonia, hemiplegia, and headache. Approximately 50% of individuals with EA2 have migraine headaches. Onset is typically in childhood or early adolescence (age range 2-32 years). Frequency of attacks can range from once or twice a year to three or four times a week. Attacks can be triggered by stress, exertion, caffeine, alcohol, fever, heat, and phenytoin and can be stopped or decreased in frequency and severity by administration of acetazolamide. Between attacks, individuals may initially be asymptomatic but eventually develop interictal findings that can include nystagmus and ataxia. MRI can demonstrate atrophy of the cerebellar vermis. EA2 is inherited in an autosomal dominant manner. Loss-of-function mutations in <italic toggle="yes">CACNA1A</italic>, which encodes for a voltage-dependent Ca<sup>2+</sup> channel alpha subunit, are causative.</p>
        <p><bold>Episodic ataxia type 3 (EA3)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/606554">606554</ext-link>) has been described in a large Canadian kindred of Mennonite heritage [<xref ref-type="bibr" rid="ea1.REF.steckley.2001.1499">Steckley et al 2001</xref>]. EA3 is an autosomal dominant episodic ataxia prominently characterized by vestibular ataxia, vertigo, tinnitus, and interictal myokymia. The age of onset is variable. The molecular genetic basis of EA3 has not been clearly established. (<xref ref-type="bibr" rid="ea1.REF.steckley.2001.1499">Steckley et al [2001]</xref> referred to this disorder as episodic ataxia type 4 [EA4]; however, the currently preferred designation is EA3.)</p>
        <p><bold>Episodic ataxia type 4 (EA4)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/606552">606552</ext-link>) (also referred to as periodic vestibulocerebellar ataxia [PATX]) has been described in families from North Carolina of northern European origin by <xref ref-type="bibr" rid="ea1.REF.farmer.1963.471">Farmer &#x00026; Mustian [1963]</xref> and <xref ref-type="bibr" rid="ea1.REF.vance.1984.78s">Vance et al [1984]</xref>. EA4 is characterized by recurrent attacks of vertigo, diplopia, and ataxia beginning in early adulthood. In some individuals, slowly progressive cerebellar ataxia occurs. Like EA3, vertigo and tinnitus are prominent in EA4; however, <xref ref-type="bibr" rid="ea1.REF.steckley.2001.1499">Steckley et al [2001]</xref> noted that EA4 differs in having abnormal eye movements, including abnormal smooth pursuit, nystagmus, and abnormal vestibuloocular reflex; no response to acetazolamide; and absence of interictal myokymia. Individuals with EA4 also displaying defective smooth pursuit, gaze-evoked nystagmus, ataxia, and vertigo have been described [<xref ref-type="bibr" rid="ea1.REF.damji.1996.338">Damji et al 1996</xref>]. The age of onset ranged from the third to the sixth decade. This condition does not link to loci identified with EA1, EA2, or spinocerebellar ataxia types 1, 2, 3, 4, and 5 [<xref ref-type="bibr" rid="ea1.REF.damji.1996.338">Damji et al 1996</xref>].</p>
        <p><bold>Episodic ataxia type 5 (EA5)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/613855">613855</ext-link>) can result from heterozygous pathogenic variants in <italic toggle="yes">CACNB4</italic>, encoding the beta-4 isoform of the regulatory beta subunit of voltage-activated Ca<sup>2+</sup> channels. A c.311G&#x0003e;T (p.Cys104Phe; reference sequences <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000726.3">NM_000726.3</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000717.2">NP_000717.2</ext-link>) pathogenic variant has been described in a French-Canadian family [<xref ref-type="bibr" rid="ea1.REF.escayg.2000.1531">Escayg et al 2000</xref>]. The phenotype was characterized by recurrent episodes of vertigo and ataxia that lasted for several hours. Interictal examination showed spontaneous downbeat and gaze-evoked nystagmus and mild dysarthria and truncal ataxia. Acetazolamide prevented the attacks. EA5 is allelic with susceptibility to juvenile myoclonic epilepsy 6 (EJM6, OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/607682">607682</ext-link>); the semiology of seizures in EA5 is similar to EJM6.</p>
        <p><bold>Episodic ataxia type 6 (EA6)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/612656">612656</ext-link>) is characterized by attacks of ataxia precipitated by fever, subclinical seizures, slurred speech followed by headache, bouts of arm jerking with concomitant confusion, alternating hemiplegia, and interictal gaze-evoked nystagmus. Attacks can be triggered by stress, fatigue, caffeine, or alcohol. EA6 can result from pathogenic variants in <italic toggle="yes">SLC1A3</italic>, which encodes the excitatory amino acid transporter 1. In cells expressing mutated proteins, glutamate uptake is reduced, suggesting that glutamate transporter dysfunction underlies the disease [<xref ref-type="bibr" rid="ea1.REF.jen.2005.529">Jen et al 2005</xref>, <xref ref-type="bibr" rid="ea1.REF.de_vries.2009.97">de Vries et al 2009</xref>].</p>
        <p><bold>Episodic ataxia type 7 (EA7)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/611907">611907</ext-link>) has been described in a four-generation family whose affected individuals showed episodic ataxia before age 20 years [<xref ref-type="bibr" rid="ea1.REF.kerber.2007.749">Kerber et al 2007</xref>]. The disease is characterized by attacks associated with weakness, vertigo, and dysarthria lasting hours to days. Attacks may be brought about by exercise and excitement. Frequency ranged from monthly to yearly and tended to decrease with age. A candidate region on chromosome 19q13, termed the EA7 locus, has been identified [<xref ref-type="bibr" rid="ea1.REF.kerber.2007.749">Kerber et al 2007</xref>].</p>
        <p><bold>Episodic ataxia type 8 (EA8)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/611907">616055</ext-link>). <xref ref-type="bibr" rid="ea1.REF.conroy.2014.505">Conroy et al [2014]</xref> reported an autosomal dominant episodic ataxia with onset in the second year of life. The attacks were characterized by unsteady gait, generalized weakness, and slurred speech. The duration and number of attacks were variable from two attacks a day (lasting minutes to hours) to two attacks per month. Two women reported improvement of symptoms during pregnancy, while others had a decrease in frequency and severity of the attacks with age. Variable additional features included twitching around the eyes, nystagmus, myokymia, mild dysarthria, and persistent intention tremor. None of the affected individuals had epilepsy, but two had migraine headache without aura. Treatment with clonazepam was effective. Genome-wide linkage analysis found linkage to an 18.5-Mb locus on chromosome 1p36.13-p34.3 between SNPs <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ensembl.org/Homo_sapiens/Variation/Summary?v=rs2743201;toggle_HGVS_names=open">rs2743201</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ensembl.org/Homo_sapiens/Variation/Summary?v=rs215791;toggle_HGVS_names=open">rs215791</ext-link> (lod score of 3.29) [<xref ref-type="bibr" rid="ea1.REF.conroy.2014.505">Conroy et al 2014</xref>]; no specific gene has been identified.</p>
        <p><bold>Spastic ataxia 1 (SPAX1)</bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/entry/108600">108600</ext-link>). Affected individuals initially show progressive leg spasticity of variable degree followed by ataxia in the form of involuntary head jerk, dysarthria, dysphagia, and ocular movement abnormalities. Age at onset is from early childhood to early twenties. SPAX1 is caused by heterozygous pathogenic variants in <italic toggle="yes">VAMP1</italic>.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="pknd" document-type="chapter"><bold>Familial paroxysmal kinesigenic dyskinesia</bold></related-object>
<bold>(PKD)</bold> is characterized by unilateral or bilateral involuntary movements precipitated by other sudden movements such as standing up from a sitting position, being startled, or changes in velocity; attacks include combinations of dystonia, choreoathetosis, and ballism, are sometimes preceded by an aura, and do not involve loss of consciousness. Attacks can be as frequent as 100 per day to as few as one per month. Attacks are usually a few seconds to five minutes in duration but can last several hours. Age of onset, severity and combinations of symptoms vary. Age of onset, typically in childhood and adolescence, ranges from four months to 57 years. The phenotype of PKD can include benign familial infantile epilepsy (BFIE), infantile convulsions and choreoathetosis (ICCA), hemiplegic migraine, migraine with and without aura, and episodic ataxia. Familial PKD is predominantly seen in males. Attack frequency is reduced or prevented by the anticonvulsants phenytoin or carbamezepine. Familial PKD is inherited in an autosomal dominant manner. Heterozygous mutations in <italic toggle="yes">PRRT2</italic> have been reported as causative of a subset of cases of familial PKD.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="pnknd" document-type="chapter"><bold>Familial paroxysmal nonkinesigenic dyskinesia</bold></related-object>
<bold>(PNKD)</bold> is characterized by unilateral or bilateral involuntary movements; attacks are spontaneous or precipitated by alcohol, caffeine or tea, excitement, stress, fatigue or chocolate. Attacks involve dystonic posturing with choreic and ballistic movements, may be accompanied by a preceding aura, occur while the individual is awake, and are not associated with seizures. Attacks last minutes to hours and occur a few times per day. Attack frequency, duration, severity, and combinations of symptoms vary within and among families. Age of onset is typically in childhood or early teens, but can be as late as age 50 years. Familial PNKD is inherited in an autosomal dominant manner and can be caused by pathogenic variants in <italic toggle="yes">PNKD</italic> (<italic toggle="yes">MR1</italic>).</p>
        <p><bold>Isaac&#x02019;s syndrome</bold> (acquired neuromyotonia, NMT) is a rare neuromuscular disorder characterized by hyperexcitability of the motor nerve that results in continuously contracting or twitching muscles (myokymia) and muscle hypertrophy. Individuals also experience cramping, increased sweating, and delayed muscle relaxation. Stiffness is most prominent in limb and trunk muscles. Symptoms are not usually triggered by exercise and occur even during sleep or when individuals are under general anesthesia. A few affected individuals report sleep disorders, anxiety, and memory loss (Morvan syndrome). Onset is between ages 15 and 60 years. The acquired form occasionally develops in association with peripheral neuropathies or after radiation treatment. Twenty percent of affected individuals have an associated thymoma. Antibodies that involves K<sup>+</sup> channels have been detected in approximately 40% of affected individuals [<xref ref-type="bibr" rid="ea1.REF.hart.2002.1887">Hart et al 2002</xref>]. Several of these auto-antibodies do not bind directly with Kv1.1, Kv1.2, or Kv1.6 channels, as previously believed, but rather to associated proteins such as leucine-rich glioma-inactivated protein 1, contactin-associated protein-like 2, contactin-2, or others as yet unidentified [<xref ref-type="bibr" rid="ea1.REF.irani.2010.2734">Irani et al 2010</xref>, <xref ref-type="bibr" rid="ea1.REF.lai.2010.776">Lai et al 2010</xref>, <xref ref-type="bibr" rid="ea1.REF.lancaster.2011.179">Lancaster et al 2011</xref>].</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS160120">Episodic Ataxia: OMIM Phenotypic Series</ext-link>, a table of similar phenotypes that are genetically diverse.</p>
      </sec>
      <sec id="ea1.Management_1">
        <title>Management</title>
        <sec id="ea1.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with episodic ataxia type 1, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Detailed medical history of the individual</p>
            </list-item>
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>Initiation (and observation) of attacks of ataxia by either mild exercise or vestibular stimuli</p>
            </list-item>
            <list-item>
              <p>EMG to confirm the presence of myokymia, particularly if it is not visible on examination</p>
            </list-item>
            <list-item>
              <p>EEG to evaluate for epilepsy [<xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>, <xref ref-type="bibr" rid="ea1.REF.chen.2007.131">Chen et al 2007</xref>]</p>
            </list-item>
            <list-item>
              <p>Consultation with a medical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="ea1.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Several drugs variably improve symptoms in affected individuals but, with the lack of clinical trials comparing the efficacy of these drugs, no single medication has been proven to be very effective. Thus, response to the following treatments may be poor.</p>
          <p><bold>Acetazolamide</bold>
<bold>(ACTZ)</bold>, a carbonic-anhydrase (CA) inhibitor, may reduce the frequency and severity of the attacks in some but not all affected individuals. The mechanism by which ACTZ reduces the frequency and severity of the attacks is unclear. The recommended starting dosage is 125 mg once a day, given orally. However, individuals with good renal function may require higher daily doses, ranging from 8 to 30 mg/kg/day in one to four divided doses (not to exceed 1 g/day). ACTZ should not be prescribed to individuals with liver, renal, or adrenal insufficiency.</p>
          <p>Chronic treatment with ACTZ may result in side effects including tiredness, paresthesias, rash, and formation of renal calculi; therefore, for some affected individuals treatment must be discontinued [<xref ref-type="bibr" rid="ea1.REF.graves.2014.1009">Graves et al 2014</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>].</p>
          <p><bold>Antiepileptic drugs</bold>
<bold>(AEDs)</bold> may significantly reduce the frequency of the attacks in responsive individuals; however, the response is heterogeneous as some individuals are particularly resistant to drugs [<xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>].</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Diphenylhydantoin</bold> treatment at a dose of 150-300 mg daily resulted in reasonable control of seizures in some individuals [<xref ref-type="bibr" rid="ea1.REF.vandyke.1975.109">VanDyke et al 1975</xref>]. In particular, phenytoin treatment at a dose of 3.7 mg/kg/day may improve muscle stiffness and motor performance [<xref ref-type="bibr" rid="ea1.REF.kinali.2004.689">Kinali et al 2004</xref>]. Nevertheless, phenytoin should be used with caution in young individuals, as it may cause permanent cerebellar dysfunction and atrophy [<xref ref-type="bibr" rid="ea1.REF.de_marcos.2003.312">De Marcos et al 2003</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Sulthiame</bold> 50-200 mg daily may reduce the attack rate. During this treatment abortive attacks were still noticed lasting a few seconds and troublesome side effects were paresthesias and intermittent carpal spasm.</p>
            </list-item>
            <list-item>
              <p><bold>Carbamazepine</bold> has been prescribed in doses up to 1600 mg daily [<xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>]. The dose needs to be adjusted according to different factors including, age, weight, the particular carbamazepine product being used, responsiveness of the individual, and other medications being taken.</p>
            </list-item>
            <list-item>
              <p><bold>Lamotrigine</bold> ameliorates attacks in some affected individuals and therefore it has been proposed as an alternative treatment [<xref ref-type="bibr" rid="ea1.REF.graves.2014.1009">Graves et al 2014</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="ea1.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>In addition to the pharmacologic treatments mentioned above, behavioral measures such as avoidance of stress, abrupt movements, loud noises or caffeine intake may be used to reduce disease manifestations in either a symptomatic or an asymptomatic person.</p>
        </sec>
        <sec id="ea1.Prevention_of_Secondary_Complication">
          <title>Prevention of Secondary Complications</title>
          <p>Contractures occur in a small proportion of individuals and can be prevented by appropriate physiotherapy.</p>
        </sec>
        <sec id="ea1.Surveillance">
          <title>Surveillance</title>
          <p>Surveillance should include annual neurologic examination.</p>
        </sec>
        <sec id="ea1.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Known triggers of attacks should be avoided; physical exertion, emotional stress, and changes in environmental temperature are the most common triggers.</p>
          <p>Marked generalized myokymia has been reported during induction of anesthesia [<xref ref-type="bibr" rid="ea1.REF.kinali.2004.689">Kinali et al 2004</xref>].</p>
        </sec>
        <sec id="ea1.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic relatives at risk in order to identify as early as possible those who would benefit from behavioral measures and avoidance of caffeine intake. If the pathogenic variant in the family is known, molecular genetic testing can be used to clarify the genetic status of at-risk relatives.</p>
          <p>See <xref ref-type="sec" rid="ea1.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="ea1.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>No published literature addresses management of the pregnancy of an affected mother or the effect of maternal EA1 on a fetus. However, affected women should be made aware that pregnancy may trigger attacks [<xref ref-type="bibr" rid="ea1.REF.graves.2014.1009">Graves et al 2014</xref>] and the possible loss of balance and fall could endanger the fetus&#x02019;s life. Moreover, several stressors that trigger attacks may cause breathing difficulties, thus, delivery by C-section should be considered.</p>
        </sec>
        <sec id="ea1.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="ea1.Other">
          <title>Other</title>
          <p>Morphologic studies on lateral gastrocnemius (LG) muscles derived from a mouse model of EA1 did not reveal changes in muscle mass, fiber type composition, or vascularization [<xref ref-type="bibr" rid="ea1.REF.brunetti.2012.310">Brunetti et al 2012</xref>].</p>
          <p>Homozygous Val408Ala/Val408Ala pathogenic variants are embryonically lethal in an animal model of EA1 [<xref ref-type="bibr" rid="ea1.REF.herson.2003.378">Herson et al 2003</xref>], although this has not been reported in humans.</p>
        </sec>
      </sec>
      <sec id="ea1.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="ea1.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Episodic ataxia type 1 (EA1) is inherited in an autosomal dominant manner.</p>
        </sec>
        <sec id="ea1.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with EA1 have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with episodic ataxia type 1 may have the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is unknown. When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, the pathogenic variant is likely <italic toggle="yes">de novo</italic>.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">KCNA1</italic> pathogenic variant found in the proband cannot be detected in leukocyte DNA of either parent, two possible explanations are germline mosaicism in a parent or <italic toggle="yes">de novo</italic> mutation in the proband. Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include neurologic evaluation and sequence analysis of <italic toggle="yes">KCNA1</italic>.</p>
            </list-item>
            <list-item>
              <p>The family history of some individuals diagnosed with EA1 may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate neurologic evaluation and molecular genetic testing have been performed on the parents of the proband.Note: If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk for the disorder because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">KCNA1</italic> pathogenic variant found in the proband cannot be detected in the leukocyte DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with EA1 has a 50% chance of inheriting the <italic toggle="yes">KCNA1</italic> pathogenic variant.</p>
          <p>
            <bold>Other family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to other family members depends on the status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent is affected, his or her family members may be at risk.</p>
            </list-item>
          </list>
        </sec>
        <sec id="ea1.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="ea1.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> pathogenic variant.</bold> When neither parent of a proband with an autosomal dominant condition has the pathogenic variant or clinical evidence of the disorder, the variant is likely <italic toggle="yes">de novo</italic>. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could be explored.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk is before pregnancy. Similarly, decisions about testing to determine the genetic status of at-risk asymptomatic family members are best made before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk of being affected.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="ea1.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the <italic toggle="yes">KCNA1</italic> pathogenic variant has been identified in an affected family member, prenatal testing for pregnancies at increased risk may be available from a clinical laboratory offering either testing of this gene or custom prenatal testing.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the <italic toggle="yes">KCNA1</italic> pathogenic variant has been identified.</p>
        </sec>
      </sec>
      <sec id="ea1.Resources">
        <title>Resources</title>
      </sec>
      <sec id="ea1.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="ea1.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Voltage-gated potassium channels (Kv) play key roles in neurotransmission and nerve cell physiology. Kv channels shorten the duration of action potentials, modulate the release of neurotransmitters, and control the excitability, electrical properties, and firing pattern of central and peripheral neurons [<xref ref-type="bibr" rid="ea1.REF.hille.2001">Hille 2001</xref>, <xref ref-type="bibr" rid="ea1.REF.pessia.2004">Pessia 2004</xref>]. In particular, Kv1.1 channels (encoded by <italic toggle="yes">KCNA1</italic>) regulate neuromuscular transmission, control the release of &#x003b2;-aminobutyric acid (GABA) from cerebellar basket cells onto Purkinje cells [<xref ref-type="bibr" rid="ea1.REF.herson.2003.378">Herson et al 2003</xref>], and modulate synaptic transmission in hippocampus [<xref ref-type="bibr" rid="ea1.REF.geiger.2000.927">Geiger &#x00026; Jonas 2000</xref>].</p>
          <p>Nomenclature of Kv channels is organized by subfamilies based on sequence relatedness by using the abbreviation Kvx.y whereby the prefix specifies both the permeating ion (K<sup>+</sup>) and the voltage-dependence of the channel (v). According to this standardized nomenclature Shaker-related channels have been classified in the subfamily Kv1.x and each member numbered Kv1.1 through Kv1.9. The same criteria have been used to classify auxiliary subunits (Kv&#x003b2;1.1 and Kv&#x003b2;1.2) and channels related to the subfamilies <italic toggle="yes">Shab</italic> (Kv2.1 and Kv2.2), <italic toggle="yes">Shaw</italic> (Kv3.1 to 3.4) and <italic toggle="yes">Shal</italic> (Kv4.1 to Kv4.3).</p>
          <p>Functional homomeric Kv1.1 channels are tetrameric structures composed of four identical monomers. Each monomer is encoded by <italic toggle="yes">KCNA1</italic>. However, potassium channel diversity is greatly enhanced by the ability of different types of pore-forming subunits to heteropolymerize and to form channels with properties different from the parental homomeric channels. Kv channels may exhibit fast <italic toggle="yes">N-type</italic> inactivation that is caused by a &#x0201c;ball-and-chain&#x0201d; mechanism of pore occlusion. Fast inactivation may be conferred to non-inactivating channels by auxiliary subunits such as Kv&#x003b2;1.1 and Kv&#x003b2;1.2. Four &#x003b2; subunits participate to the ion channel complex and provide four inactivation particles. Notable examples:</p>
          <list list-type="bullet">
            <list-item>
              <p>Heteromeric channels composed of Kv1.1 and Kv1.2 that are expressed at cerebellar basket cell terminals and at the juxtaparanodal region of motor axons</p>
            </list-item>
            <list-item>
              <p>Channels composed of Kv1.1, Kv1.4, and Kv&#x003b2;1.1 subunits that are expressed in hippocampal mossy fiber boutons</p>
            </list-item>
          </list>
          <p>Kv1.1 channels possess a slower process of inactivation, which has been named <bold>C-type</bold> or <bold>P-type</bold> depending on the structural determinants of this process that have been located within the C-terminus and pore region.</p>
          <p>D&#x02019;Adamo et al first demonstrated that proteins encoded by <italic toggle="yes">KCNA1</italic> pathogenic variants associated with EA1 alter the expression and gating properties of heteromeric channels composed of human Kv1.2 and Kv1.1 subunits [<xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.rea.2002.5">Rea et al 2002</xref>]. Successively, it has been shown that proteins encoded by <italic toggle="yes">KCNA1</italic> pathogenic variants also impair the function of hetero-oligomeric complexes comprising Kv1.1, Kv1.4, and Kv&#x003b2;1.x subunits in distinct ways [<xref ref-type="bibr" rid="ea1.REF.imbrici.2006.3073">Imbrici et al 2006</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</xref>]. These studies raised the question as to whether other allelic variations, whose gene products may or may not form hetero-oligomeric complexes with Kv1.1 subunits, may underlie a similar channelopathy.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">KCNA1</italic> has a transcript of 7983 nucleotides with a coding region of 1488. There are two exons, but the coding region is located entirely within exon 2. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="ea1" object-id="ea1.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Benign allelic variants.</bold> In 5% of control chromosomes analyzed by <xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al [1999]</xref>, two silent changes in the coding sequence were observed, c.684T&#x0003e;C and c.804G&#x0003e;C (see <xref ref-type="table" rid="ea1.T.selected_kcna1_allelic_variants">Table 2</xref>). The reference sequences in <xref ref-type="table" rid="ea1.T.selected_kcna1_allelic_variants">Table 2</xref> include the correction of a sequence error published by <xref ref-type="bibr" rid="ea1.REF.ramaswami.1990.214">Ramaswami et al [1990]</xref> and reported by <xref ref-type="bibr" rid="ea1.REF.browne.1994.136">Browne et al [1994]</xref> and <xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al [1999]</xref>.</p>
          <p><bold>Pathogenic allelic variants.</bold> To date, <italic toggle="yes">KCNA1</italic> pathogenic variants have been identified by sequence analysis (see <xref ref-type="fig" rid="ea1.F1">Figure 1</xref>). Most are missense variants that are distributed throughout the gene; however, nonsense variants and small deletions have also been identified [<xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>, <xref ref-type="bibr" rid="ea1.REF.shook.2008.399">Shook et al 2008</xref>].</p>
          <p>Interestingly, four different variants of the highly conserved threonine 226 residue, located within the second transmembrane segment, have been identified [<xref ref-type="bibr" rid="ea1.REF.rajakulendran.2007.258">Rajakulendran et al 2007</xref>]. In particular, the amino acid change p.Thr226Arg is associated with epilepsy, infantile contractures, postural abnormalities, and skeletal deformities. Although, the defects caused by the p.Thr226Ala, p.Thr226Arg, and p.Thr226Met amino acid changes on channel functions are virtually identical, they lead to diverse phenotypes.</p>
          <table-wrap id="ea1.T.selected_kcna1_allelic_variants" position="anchor" orientation="portrait">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">KCNA1</italic> Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.684T&#x0003e;C<break/>(C684T)</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_4" rowspan="10" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000217.2">NM_000217.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000208.2">NP_000208.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.804G&#x0003e;C<break/>(C804G)</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.=&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_1" rowspan="8" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.676A&#x0003e;G</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr226Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.677C&#x0003e;G</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr226Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.677C&#x0003e;T</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr226Met</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1223T&#x0003e;C</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val408Ala</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1222G&#x0003e;T</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Val408Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1241T&#x0003e;G</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe414Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1249C&#x0003e;T</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg417Ter</td>
                </tr>
                <tr>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.748_750delTTC</td>
                  <td headers="hd_h_ea1.T.selected_kcna1_allelic_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Phe250del</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="ea1.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="ea1.TF.2.2">
                <label>2. </label>
                <p>p.= designates that protein has not been analyzed, but no change is expected.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">KCNA1</italic> encodes the voltage-gated K<sup>+</sup> channel Kv1.1. The predicted 496-amino acid Kv1.1 protein contains six hydrophobic segments with the N- and C-termini residing inside the cell. The S4 segment of each Kv1.1 subunit comprises the main voltage sensor that opens the channel by undergoing a conformational rearrangement on membrane depolarization. The S5-S6 loop (H5 region) contributes to the ion-conducting pore. The GYG residues, residing within this loop, control the K<sup>+</sup> selectivity of the channel (see also <xref ref-type="sec" rid="ea1.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
          <p><bold>Abnormal gene product.</bold> The molecular mechanisms underlying episodic ataxia type 1 have been established by determining the functional properties of wild-type and several mutant channels in <italic toggle="yes">Xenopus</italic> oocytes or mammalian cell lines [<xref ref-type="bibr" rid="ea1.REF.adelman.1995.1449">Adelman et al 1995</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.1998.1200">D&#x02019;Adamo et al 1998</xref>, <xref ref-type="bibr" rid="ea1.REF.zerr.1998.2842">Zerr et al 1998</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.zuberi.1999.817">Zuberi et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.eunson.2000.647">Eunson et al 2000</xref>, <xref ref-type="bibr" rid="ea1.REF.manganas.2001.49427">Manganas et al 2001</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2003.373">Imbrici et al 2003</xref>, <xref ref-type="bibr" rid="ea1.REF.cusimano.2004.237">Cusimano et al 2004</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2006.3073">Imbrici et al 2006</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2007.c778">Imbrici et al 2007</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2008.577">Imbrici et al 2008</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2009.39">Imbrici et al 2009</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>]. Overall, these studies have shown that allelic variations underlying EA1 impair channel function and reduce the outward K<sup>+</sup> flux through the channel, although with highly variable effects on aspects of channel expression and gating.</p>
          <p>Regarding channel gating, <italic toggle="yes">KCNA1</italic> pathogenic variants may alter the protein structure and affect the kinetics of opening and closing, voltage dependence, and N- and C-type inactivation [<xref ref-type="bibr" rid="ea1.REF.d_adamo.1998.1200">D&#x02019;Adamo et al 1998</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.maylie.2002.4786">Maylie et al 2002</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2006.3073">Imbrici et al 2006</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2009.39">Imbrici et al 2009</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2011.c1314">Imbrici et al 2011</xref>, <xref ref-type="bibr" rid="ea1.REF.d_adamo.2015.525">D&#x02019;Adamo et al 2015</xref>].</p>
          <p>Individuals with EA1 are heterozygous for a <italic toggle="yes">KCNA1</italic> pathogenic variant, possessing a normal and a mutated allele, which may be equally expressed. Therefore, channels composed of wild-type and mutated subunits may be formed. Co-expression systems, which mimic the heterozygous condition, have shown that some mutant subunits exert dominant negative effects on wild-type subunits, resulting in less than half the normal current, whereas others have virtually no effect on surface expression. It has been shown that <italic toggle="yes">KCNA1</italic> allelic variations also alter the function of heteromeric channels containing different subunits, demonstrating that pathogenic variants in a single gene disrupt the functions of other closely related proteins [<xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, <xref ref-type="bibr" rid="ea1.REF.rea.2002.5">Rea et al 2002</xref>, <xref ref-type="bibr" rid="ea1.REF.imbrici.2006.3073">Imbrici et al 2006</xref>]. Based on these findings, a model accounting for the cerebellar symptoms of EA1 was proposed by D&#x02019;Adamo and colleagues (see <xref ref-type="fig" rid="ea1.F2">Figure 2</xref>).</p>
          <p>A mouse model of EA1 has been generated by introducing a pathogenic variant analogous to the human p.Val408Ala pathogenic variant into the murine ortholog, <italic toggle="yes">Kcna1.</italic> These animals showed impaired motor performance and altered cerebellar GABAergic transmission from the basket cells to the Purkinje cells [<xref ref-type="bibr" rid="ea1.REF.herson.2003.378">Herson et al 2003</xref>]. Such <italic toggle="yes">Kv1.1</italic> knock-in ataxic mice also exhibited spontaneous myokymic activity exacerbated by fatigue, ischemia, and low temperature [<xref ref-type="bibr" rid="ea1.REF.brunetti.2012.310">Brunetti et al 2012</xref>]. Spontaneous myokymic discharges were present despite motor nerve axotomy, suggesting that the motor nerve is an important generator of myokymic activity. This study also showed that altered Ca<sup>2+</sup> homeostasis in motor axons of mutant animals may contribute to spontaneous myokymic activity [<xref ref-type="bibr" rid="ea1.REF.brunetti.2012.310">Brunetti et al 2012</xref>].</p>
          <p>The causes that trigger the paroxysms of ataxia remain elusive, although a phenomenon akin to spreading acidification of the cerebellar cortex has been suggested [<xref ref-type="bibr" rid="ea1.REF.chen.2005.1287">Chen et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="ea1.References">
        <title>References</title>
        <sec id="ea1.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="ea1.Literature_Cited.reflist0">
            <ref id="ea1.REF.adelman.1995.1449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Adelman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bond</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>Episodic ataxia results from voltage-dependent potassium channels with altered functions.</article-title>
                <source>Neuron</source>
                <volume>15</volume>
                <fpage>1449</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">8845167</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.browne.1994.136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Browne</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gancher</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nutt</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunt</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kramer</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Litt</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1994</year>
                <article-title>Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1.</article-title>
                <source>Nat Genet</source>
                <volume>8</volume>
                <fpage>136</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">7842011</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.brunetti.2012.310">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brunetti</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Botti</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettorossi</surname>
                    <given-names>VE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zammit</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mora</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibertini</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Giovanni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muscat</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Kv1.1 knock-in ataxic mice exhibit spontaneous myokymic activity exacerbated by fatigue, ischemia and low temperature.</article-title>
                <source>Neurobiol Dis.</source>
                <volume>47</volume>
                <fpage>310</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">22609489</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.chen.2005.1287">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reinert</surname>
                    <given-names>KC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Popa</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hendrix</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ross</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebner</surname>
                    <given-names>TJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Involvement of Kv1 potassium channels in spreading acidification and depression in the cerebellar cortex.</article-title>
                <source>J Neurophysiol.</source>
                <volume>94</volume>
                <fpage>1287</fpage>
                <lpage>98</lpage>
                <pub-id pub-id-type="pmid">15843481</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.chen.2007.131">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Hehn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaczmarek</surname>
                    <given-names>LK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ment</surname>
                    <given-names>LR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pober</surname>
                    <given-names>BR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hisama</surname>
                    <given-names>FM</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Functional analysis of a novel potassium channel (KCNA1) mutation in hereditary myokymia.</article-title>
                <source>Neurogenetics</source>
                <volume>8</volume>
                <fpage>131</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">17136396</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.conroy.2014.505">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Conroy</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGettigan</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Webb</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCoy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Albertyn</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCreary</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonagh</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walsh</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lynch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ennis</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>A novel locus for episodic ataxia:UBR4 the likely candidate.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2014</year>
                <volume>22</volume>
                <fpage>505</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">23982692</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.cusimano.2004.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cusimano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>An episodic ataxia type-1 mutation in the S1 segment sensitises the hKv1.1 potassium channel to extracellular Zn2+.</article-title>
                <source>FEBS Lett.</source>
                <volume>576</volume>
                <fpage>237</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">15474044</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.d_adamo.2015.525">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallenm&#x000fc;ller</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servettini</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartl</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arning</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biskup</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grottesi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guglielmi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernasconi</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Di Giovanni</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franciolini</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Catacuzzeno</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopstock</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Novel phenotype associated with a mutation in the KCNA1(Kv1.1) gene.</article-title>
                <source>Front Physiol.</source>
                <year>2015</year>
                <volume>5</volume>
                <fpage>525</fpage>
                <pub-id pub-id-type="pmid">25642194</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.d_adamo.2012">
              <mixed-citation publication-type="book">D&#x02019;Adamo MC, Imbrici P, Di Giovanni G, Pessia M. The neurobiology of episodic ataxia type 1: a Shaker-like K+ channel disorder. In: Hong SH, ed. <italic toggle="yes">Ataxia: Causes, Symptoms and Treatment.</italic> New York, NY: Nova Science Publishers; 2012:47-75.</mixed-citation>
            </ref>
            <ref id="ea1.REF.d_adamo.1999.1335">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sponcichetti</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Mutations in the KCNA1 gene associated with episodic ataxia type-1 syndrome impair heteromeric voltage-gated K(+) channel function.</article-title>
                <source>FASEB J</source>
                <volume>13</volume>
                <fpage>1335</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">10428758</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.d_adamo.1998.1200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adelman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Episodic ataxia type-1 mutations in the hKv1.1 cytoplasmic pore region alter the gating properties of the channel.</article-title>
                <source>EMBO J</source>
                <volume>17</volume>
                <fpage>1200</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9482717</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.damji.1996.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Damji</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Allingham</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pollock</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Small</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lewis</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stajich</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaoka</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <article-title>Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias.</article-title>
                <source>Arch Neurol.</source>
                <year>1996</year>
                <volume>53</volume>
                <fpage>338</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">8929156</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.de_marcos.2003.312">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>De Marcos</surname>
                    <given-names>FA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghizoni</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobayashi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cendes</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>Cerebellar volume and long-term use of phenytoin.</article-title>
                <source>Seizure.</source>
                <year>2003</year>
                <volume>12</volume>
                <fpage>312</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">12810345</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.demos.2009.778">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Demos</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macri</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farrell</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>TN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chapman</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Accili</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Armstrong</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A novel KCNA1 mutation associated with global delay and persistent cerebellar dysfunction.</article-title>
                <source>Mov Disord</source>
                <volume>24</volume>
                <fpage>778</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">19205071</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.de_vries.2009.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamsa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stam</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakker</surname>
                    <given-names>SLM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanmolkot</surname>
                    <given-names>KRJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Terwindt</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boon</surname>
                    <given-names>EMJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frants</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>MD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Maagdenberg</surname>
                    <given-names>AMJM</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Episodic ataxia associated with EAAT1 mutation C186S affecting glutamate reuptake.</article-title>
                <source>Arch Neurol</source>
                <volume>66</volume>
                <fpage>97</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">19139306</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.escayg.2000.1531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Escayg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Waard</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bichet</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayer</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sander</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meisler</surname>
                    <given-names>MH</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia.</article-title>
                <source>Am J Hum Genet</source>
                <volume>66</volume>
                <fpage>1531</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10762541</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.eunson.2000.647">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Eunson</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rea</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuberi</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Youroukos</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Panayiotopoulos</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liguori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Avoni</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWilliam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spauschus</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.</article-title>
                <source>Ann Neurol</source>
                <volume>48</volume>
                <fpage>647</fpage>
                <lpage>56</lpage>
                <pub-id pub-id-type="pmid">11026449</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.farmer.1963.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Farmer</surname>
                    <given-names>TW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mustian</surname>
                    <given-names>VM</given-names>
                  </name>
                </person-group>
                <year>1963</year>
                <article-title>Vestibulo-cerebellar ataxia: a newly defined hereditary syndrome with periodic manifestations.</article-title>
                <source>Arch Neurol</source>
                <volume>8</volume>
                <fpage>471</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">13944410</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.geiger.2000.927">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Geiger</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonas</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Dynamic control of presynaptic Ca(2+) inflow by fast-inactivating K(+) channels in hippocampal mossy fiber boutons.</article-title>
                <source>Neuron</source>
                <volume>28</volume>
                <fpage>927</fpage>
                <lpage>39</lpage>
                <pub-id pub-id-type="pmid">11163277</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.glaudemans.2009.936">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glaudemans</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Wijst</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scola</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lorenzoni</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heister</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Kemp</surname>
                    <given-names>AW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knoers</surname>
                    <given-names>NV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoenderop</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindels</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A missense mutation in the Kv1.1 voltage-gated potassium channel-encoding gene KCNA1 is linked to human autosomal dominant hypomagnesemia.</article-title>
                <source>J Clin Invest</source>
                <volume>119</volume>
                <fpage>936</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">19307729</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.graves.2014.1009">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Graves</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cha</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hahn</surname>
                    <given-names>AF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barohn</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salajegheh</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bundy</surname>
                    <given-names>BN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <article-title>CINCH Investigators. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation.</article-title>
                <source>Brain.</source>
                <year>2014</year>
                <volume>137</volume>
                <fpage>1009</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">24578548</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.graves.2010.367">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Graves</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rajakulendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuberi</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorge</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins.</article-title>
                <source>Neurology.</source>
                <volume>75</volume>
                <fpage>367</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">20660867</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.hart.2002.1887">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hart</surname>
                    <given-names>IK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maddison</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Newsom-Davis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mills</surname>
                    <given-names>KR</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Phenotypic variants of autoimmune peripheral nerve hyperexcitability.</article-title>
                <source>Brain</source>
                <volume>125</volume>
                <fpage>1887</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">12135978</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.herson.2003.378">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Herson</surname>
                    <given-names>PS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Virk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rustay</surname>
                    <given-names>NR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bond</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crabbe</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adelman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>A mouse model of episodic ataxia type-1.</article-title>
                <source>Nat Neurosci</source>
                <volume>6</volume>
                <fpage>378</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">12612586</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.hille.2001">
              <mixed-citation publication-type="book">Hille B. <italic toggle="yes">Ionic Channels of Excitable Membranes.</italic> 3 ed. Sunderland, MA: Sinauer; 2001.</mixed-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2003.373">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusimano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Curtis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Functional characterization of an episodic ataxia type-1 mutation occurring in the S1 segment of hKv1.1 channels.</article-title>
                <source>Pflugers Arch</source>
                <volume>446</volume>
                <fpage>373</fpage>
                <lpage>79</lpage>
                <pub-id pub-id-type="pmid">12799903</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2007.c778">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cusimano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Episodic ataxia type 1 mutation F184C alters Zn2+-induced modulation of the human K+ channel Kv1.4-Kv1.1/Kvbeta1.1.</article-title>
                <source>Am J Physiol Cell Physiol</source>
                <volume>292</volume>
                <fpage>C778</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">16956965</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2011.c1314">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grottesi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biscarini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Episodic ataxia type 1 mutations affect fast inactivation of K<sup>+</sup> channels by a reduction in either subunit surface expression or affinity for inactivation domain.</article-title>
                <source>Am J Physiol Cell Physiol.</source>
                <volume>300</volume>
                <fpage>C1314</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">21307345</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2006.3073">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Episodic ataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human K+ channels Kv1.4-1.1/Kvbeta1.1 and Kv1.4-1.1/Kvbeta1.2.</article-title>
                <source>Eur J Neurosci</source>
                <volume>24</volume>
                <fpage>3073</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">17156368</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2009.39">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grottesi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Contributions of the central hydrophobic residue in the PXP motif of Voltage-Dependent K+ Channels to S6 flexibility and Gating Properties.</article-title>
                <source>Channels (Austin)</source>
                <volume>3</volume>
                <fpage>39</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">19202350</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.imbrici.2008.577">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Imbrici</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gualandi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x02019;Adamo</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taddei Masieri</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cudia</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Grandis</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mannucci</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoletti</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tucker</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferlini</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pessia</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>A novel KCNA1 mutation identified in an Italian family affected by episodic ataxia type 1.</article-title>
                <source>Neuroscience</source>
                <volume>157</volume>
                <fpage>577</fpage>
                <lpage>87</lpage>
                <pub-id pub-id-type="pmid">18926884</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.irani.2010.2734">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Irani</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alexander</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kleopa</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pettingill</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zuliani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peles</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buckley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vincent</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Antibodies to Kv1 potassium channel-complex proteins leucine-rich glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis Morvan&#x02019;s syndrome and acquired neuromyotonia.</article-title>
                <source>Brain</source>
                <year>2010</year>
                <volume>133</volume>
                <fpage>2734</fpage>
                <lpage>48</lpage>
                <pub-id pub-id-type="pmid">20663977</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.jen.2005.529">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wan</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palos</surname>
                    <given-names>TP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howard</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Mutation in the glutamate transporter EAAT1 causes episodic ataxia, hemiplegia, and seizures.</article-title>
                <source>Neurology</source>
                <volume>65</volume>
                <fpage>529</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">16116111</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.kerber.2007.749">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kerber</surname>
                    <given-names>KA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>A new episodic ataxia syndrome with linkage to chromosome 19q13.</article-title>
                <source>Arch Neurol</source>
                <volume>64</volume>
                <fpage>749</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">17502476</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.kiernan.2000.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kiernan</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersen</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bostock</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Multiple measures of axonal excitability: a new approach in clinical testing.</article-title>
                <source>Muscle Nerve</source>
                <year>2000</year>
                <volume>23</volume>
                <fpage>399</fpage>
                <lpage>409</lpage>
                <pub-id pub-id-type="pmid">10679717</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.kinali.2004.689">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kinali</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eunson</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manzur</surname>
                    <given-names>AY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercuri</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Expanding the phenotype of potassium channelopathy: severe neuromyotonia and skeletal deformities without prominent Episodic Ataxia.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>14</volume>
                <fpage>689</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">15351427</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.klein.2004.147">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Klein</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boltshauser</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Episodic ataxia type 1 with distal weakness: a novel manifestation of a potassium channelopathy.</article-title>
                <source>Neuropediatrics</source>
                <volume>35</volume>
                <fpage>147</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15127317</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.lai.2010.776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huijbers</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lancaster</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graus</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bataller</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balice-Gordon</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cowell</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalmau</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.</article-title>
                <source>Lancet Neurol</source>
                <year>2010</year>
                <volume>9</volume>
                <fpage>776</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">20580615</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.lancaster.2011.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lancaster</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martinez-Hernandez</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dalmau</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Encephalitis and antibodies to synaptic and neuronal cell surface proteins.</article-title>
                <source>Neurology.</source>
                <year>2011</year>
                <volume>77</volume>
                <fpage>179</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">21747075</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.lee.2004a.536">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabatti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>SF</given-names>
                  </name>
                </person-group>
                <year>2004a</year>
                <article-title>A novel mutation in KCNA1 causes episodic ataxia without myokymia.</article-title>
                <source>Hum Mutat</source>
                <volume>24</volume>
                <fpage>536</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">15532032</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.lee.2004b.3161">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>HY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahn</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auburger</surname>
                    <given-names>GW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandolfo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwiecinski</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grimes</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lang</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nielsen</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Averyanov</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Bogaert</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abramowicz</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruno</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sorensen</surname>
                    <given-names>BF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pt&#x000e1;cek</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2004b</year>
                <article-title>The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>13</volume>
                <fpage>3161</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">15496428</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.manganas.2001.49427">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Manganas</surname>
                    <given-names>LN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akhtar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antonucci</surname>
                    <given-names>DE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campomanes</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dolly</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trimmer</surname>
                    <given-names>JS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Episodic ataxia type-1 mutations in the Kv1.1 potassium channel display distinct folding and intracellular trafficking properties.</article-title>
                <source>J Biol Chem</source>
                <volume>276</volume>
                <fpage>49427</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">11679591</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.maylie.2002.4786">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bissonnette</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Virk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adelman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>JG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Episodic ataxia type 1 mutations in the human Kv1.1 potassium channel alter hKvbeta 1-induced N-type inactivation.</article-title>
                <source>J Neurosci</source>
                <volume>22</volume>
                <fpage>4786</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">12077175</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.pessia.2004">
              <mixed-citation publication-type="book">Pessia M. Ion channels and electrical activity. In: Wayne Davies R, Morris BJ, eds. <italic toggle="yes">Molecular Biology of the Neuron.</italic> Oxford, UK: Oxford University Press; 2004:103-37.</mixed-citation>
            </ref>
            <ref id="ea1.REF.rajakulendran.2007.258">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rajakulendran</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schorge</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Episodic ataxia type 1: a neuronal potassium channelopathy.</article-title>
                <source>Neurotherapeutics.</source>
                <volume>4</volume>
                <fpage>258</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">17395136</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.ramaswami.1990.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ramaswami</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gautam</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamb</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rudy</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanauye</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mathew</surname>
                    <given-names>MK</given-names>
                  </name>
                </person-group>
                <year>1990</year>
                <article-title>Human potassium channel genes: molecular cloning and functional expression.</article-title>
                <source>Mol Cell Neurosci</source>
                <volume>1</volume>
                <fpage>214</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">19912772</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.rea.2002.5">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rea</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spauschus</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eunson</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Variable K+ channel subunit dysfunction in inherited mutations of KCNA1.</article-title>
                <source>J Physiol</source>
                <volume>538</volume>
                <fpage>5</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">11773313</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.shook.2008.399">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shook</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mamsa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jen</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Novel mutation in KCNA1 causes episodic ataxia with paroxysmal dyspnea.</article-title>
                <source>Muscle Nerve</source>
                <volume>37</volume>
                <fpage>399</fpage>
                <lpage>402</lpage>
                <pub-id pub-id-type="pmid">17912752</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.steckley.2001.1499">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Steckley</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ebers</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cader</surname>
                    <given-names>MZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McLachlan</surname>
                    <given-names>RS</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus.</article-title>
                <source>Neurology</source>
                <volume>57</volume>
                <fpage>1499</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">11673600</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.tomlinson.2010.3530">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tomlinson</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tan</surname>
                    <given-names>SV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bostock</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Nerve excitability studies characterize Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1.</article-title>
                <source>Brain.</source>
                <volume>133</volume>
                <fpage>3530</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">21106501</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.vance.1984.78s">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Payne</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coin</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olanow</surname>
                    <given-names>CW</given-names>
                  </name>
                </person-group>
                <year>1984</year>
                <article-title>Linkage and genetic analysis in adult onset periodic vestibulo-cerebellar ataxia: report of a new family.</article-title>
                <source>Am J Hum Genet</source>
                <volume>36</volume>
                <fpage>78S</fpage>
              </element-citation>
            </ref>
            <ref id="ea1.REF.vandyke.1975.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>VanDyke</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griggs</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murphy</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goldstein</surname>
                    <given-names>MN</given-names>
                  </name>
                </person-group>
                <article-title>Hereditary myokymia and periodic ataxia.</article-title>
                <source>J Neurol Sci.</source>
                <year>1975</year>
                <volume>25</volume>
                <fpage>109</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">1170284</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.zerr.1998.2842">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zerr</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adelman</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maylie</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Episodic ataxia mutations in Kv1.1 alter potassium channel function by dominant negative effects or haploinsufficiency.</article-title>
                <source>J Neurosci</source>
                <volume>18</volume>
                <fpage>2842</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9526001</pub-id>
              </element-citation>
            </ref>
            <ref id="ea1.REF.zuberi.1999.817">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zuberi</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eunson</surname>
                    <given-names>LH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spauschus</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Silva</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tolmie</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>NW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McWilliam</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kullmann</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>MG</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy.</article-title>
                <source>Brain</source>
                <volume>122</volume>
                <fpage>817</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">10355668</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="ea1.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="ea1.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The financial support of Telethon (GGP11188), Ministero della Salute (GR-2009-1580433), and Fondazione Cassa di Risparmio di Perugia to MP is gratefully acknowledged. MGH is supported by an MRC Centre Grant (G0601943).</p>
        </sec>
        <sec id="ea1.Author_History">
          <title>Author History</title>
          <p>Maria Cristina D&#x02019;Adamo, PhD (2010-present)Giuseppe Di Giovanni, PhD; Istituto Euro-Mediterraneo di Scienza e Tecnologia (2012-2015)Michael G Hanna, BSc (Hons), MD, FRCP; UCL Institute of Neurology (2010-2015)Mauro Pessia, PhD; Istituto Euro-Mediterraneo di Scienza e Tecnologia (2010-2015)</p>
        </sec>
        <sec id="ea1.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>25 June 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>16 August 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>9 February 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>21 April 2009 (mp) Initial submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="ea1.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Schematic drawing of the conventional membrane topology of a human Kv1.1 subunit. Four such subunits comprise a functional homotetrameric channel. Different subunits belonging to the Kv1 subfamily may form heterotetrameric channels. The positions of pathogpenic variants identified to date in individuals with EA1 are indicated. Modified from <xref ref-type="bibr" rid="ea1.REF.d_adamo.2012">D&#x02019;Adamo et al [2012]</xref>; used by permission of Nova Science Publishers, Inc.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ea1-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="ea1.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Proposed effects of EA1-causing pathogenic variants on basket cell and Purkinje cell inhibitory outputs. The diagram shows a basket cell which has synapses on the initial segment and soma of a number of Purkinje cells from the cerebellar cortex of a normal individual (<italic toggle="yes">left</italic>) compared to an individual with EA1 (<italic toggle="yes">right</italic>). The reduced delayed rectifier function of EA1 heteromeric channels comprising Kv1.1 and Kv1.2 subunits, which are expressed at the presynaptic level of basket cells, may increase the membrane excitability, prolong their action potential duration, and enhance Ca<sup>2+</sup> ion influx. Larger amounts of &#x003b3;-aminobutyric acid (GABA) may be released from basket cell terminals reducing the inhibitory outputs of the relevant Purkinje cells. As a result, the output of the entire cerebellum to the rest of the brain may be markedly altered leading to the cerebellar symptoms characteristic of EA1 syndrome (see <xref ref-type="bibr" rid="ea1.REF.d_adamo.1999.1335">D&#x02019;Adamo et al 1999</xref>, Figure 7).Reused by permission of FASEB Journal</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ea1-Image002" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
